Inclusion is bigger than policy or workplace acronyms. It’s a way of living and fostering greater outcomes, writes Novo ...

Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna ...

On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path.

On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer.

This article examines FDA guidance on payment and reimbursement for clinical trial participants, with commentary highlighting key considerations for ethical and effective compensation. It clarifies ...

Empirical research comparing corporate and academic spin-offs consistently shows that corporate-originated ventures outperform their academic counterparts in terms of growth and survival. This ...

Artificial intelligence is reshaping drug discovery, but its integration raises critical questions: How do we balance AI-driven insights with data integrity, human expertise, and ethical ...

Novartis is making a major investment in North Carolina’s Research Triangle, committing $771 million across three projects that will strengthen U.S. pharmaceutical manufacturing. The expansion ...

On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during ...

Q3 2025 delivered meaningful momentum across the gene, cell, and RNA therapy landscape, highlighted by four global approvals. China’s NMPA cleared Hrain Biotechnology’s Hicara CAR-T for large B-cell ...

In the July issue of Life Science Leader, Cliff Mintz wrote a global update on follow-on biologics in unregulated markets, the European Union, and the United States. With intense public debate around ...

Having been in the industry for more than 25 years, Patrick Guertin knows that cells can be temperamental and don’t like to be rushed, but in today’s biopharma industry speed to market is key. Guertin ...